合理的に設計されたレドックス活性Au ((I) N-ヘテロサイクルカルベン:免疫細胞死誘導体
Sajal Sen1, Stephanie Hufnagel2, Esther Y Maier3
1Department of Chemistry, The University of Texas at Austin, 105 East 24th Street, Austin, Texas 78712, United States.
Journal of the American Chemical Society
|November 25, 2020
まとめ
研究者達は 免疫細胞死 (ICD) を誘発する新種の黄金化合物を開発しました 免疫系が腫瘍と闘うように 誘発するプロセスです この新しいアプローチは 癌細胞に対する 身体の自然な防御を強化することで 癌治療の有望性を示しています
科学分野:
- 腫瘍学
- 免疫学
- 材料科学
背景:
- 免疫細胞死 (ICD) は,腫瘍細胞に対する免疫反応を誘発するプログラム細胞死メカニズムである.
- ICDを誘発する現在の治療法は,有効性と範囲が限られています.
- ICDを効果的に誘発し,抗がん効果を向上させる新しい治療薬が必要です.
研究 の 目的:
- 新しい酸化還元活性金 (((I) ビス-N-ヘテロサイクルカルベン (Au (((I) -NHC) 複合体を設計し,合成する.
- このAu (I) -NHC複合体の免疫細胞死 (ICD) をインビトロおよびインビボで誘導する可能性を調査する.
- 非対称な酸化還元活性Au (I) -NHC複合体の容易な製造のための合成経路を確立する.
主な方法:
- 合理的に設計されたリドックス活性Au ((I)) ビス-N-ヘテロサイクルカルベンの合成.
- ICDのバイオマーカーのインビトロ評価 (例えば,カルレチクリン暴露,ATPの放出,HMGB1の転位).
- 臨床前モデルにおける抗がん効果と免疫応答のインビボ評価
主要な成果:
- 合成されたAu (I) -NHC複合体は,ICDバイオマーカーをインビトロで強力に誘導することが示された.
- この化合物は,免疫系活性化に関連して,体内において有意な抗がん活性を示した.
- 非対称的な酸化還元活性Au ((I) -NHC化合物を生成するための簡単な合成経路が開発された.
結論:
- 新種のリドックス活性Au ((I)) -NHC複合体は,免疫細胞死亡を誘導することで,がん免疫療法の有望な候補である.
- この研究は,がん治療戦略における 金基化合物の可能性を強調しています.
- 開発された合成方法論は,さらなる調査のために多様なAu ((I) -NHC構造を生成することを可能にします.
関連する概念動画
Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for the...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...


